Category Archives: Erectile Dysfunction

Newswise In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with radiation. The findings, to be published online September 27, 2012, in advance of the October 1, 2012 print issue in the International Journal of Radiation Oncology Biology Physics, the official scientific journal of the American Society for Radiation Oncology, are an important step towards helping clinicians determine the best course of treatment for prostate cancer patients and may lead to the development of therapies that alleviate side effects. The main treatments for prostate cancer surgery, brachytherapy (seed implants) and external beam radiation therapy are all very effective at curing prostate cancer. Unfortunately, each treatment places patients at risk for ED. According to the National Cancer Institute, the prevalence of erectile dysfunction following external beam radiation for prostate cancer ranges from 65 percent to 85 percent. The Prostate Cancer Foundation estimates prevalence of ED following seed therapy at 25 to 50 percent. Many men will be able to regain their potency with time and … Continue reading →

Eli Lilly and Companys (LLY) Cialis (tadalafil) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (:EMA). The CHMP issued an opinion in favor of approving Eli Lillys erectile dysfunction (ED) drug, Cialis (5 mg), for the once-daily treatment of the signs and symptoms of benign prostatic hyperplasia (:BPH). A response from the European Commission regarding Cialis regulatory status should be out in two months. The CHMPs opinion was based on a review of safety and efficacy data on 1,500 patients from four clinical studies of BPH, including a study of BPH and ED. Cialis label expansion would provide patients suffering from both ED and BPH with a new treatment option. Approval for the additional indication will help boost Cialis sales, which came in at $1.9 billion in 2011. Cialis, which is approved for the treatment of ED in the EU, is approved for the treatment of ED as well as the treatment of BPH in the US. Cialis main competitors in the ED market include Pfizers (PFE) Viagra and GlaxoSmithKlines (GSK) Levitra. The BPH market is also pretty crowded with products like Glaxo's Avodart and Jalyn, Sanofis (SNY) … Continue reading →

Impotence or erectile dysfunction is not an uncommon phenomenon. Globally, men experience the condition for different reasons. Some may seek treatment while others may suffer embarrassment and not get the care they need to improve the quality of their sexual experience. Impotence may have a physical, medicational, or psychological basis. Researchers strive to find a cure for impotence. There are varied treatments available depending on the cause of impotence, however some do not offer a cure for the underlying cause and others treat impotence symptoms. Erectile dysfunction is diagnosed through discussion, physical examination, blood and laboratory tests, ultrasound and neurological testing. Disease, injury, and stress may affect erections and ability to have orgasm. Treatments for physical causes of impotence include medications, hormone therapy, vacuum pumps, surgery and Kegel exercises. Psychological causes of erectile dysfunction may be treated through exercise, counselling, talk therapy and Cognitive Behavioural Therapy (CBT). Low intensity shockwave therapy A new innovation in impotence treatment is electric shock therapy. The therapy is developed by Israeli scientists from Haifa Rambam Medical Centre and is now available at Spire Murrayfield Hospital in Edinburgh, Scotland. Considered safe, non-invasive and pain-free, the electric shock therapy works by stimulating blood flow to the … Continue reading →

Impotence or erectile dysfunction is not an uncommon phenomenon. Globally, men experience the condition for different reasons. Some may seek treatment while others may suffer embarrassment and not get the care they need to improve the quality of their sexual experience. Impotence may have a physical, medicational, or psychological basis. Researchers strive to find a cure for impotence. There are varied treatments available depending on the cause of impotence, however some do not offer a cure for the underlying cause and others treat impotence symptoms. Erectile dysfunction is diagnosed through discussion, physical examination, blood and laboratory tests, ultrasound and neurological testing. Disease, injury, and stress may affect erections and ability to have orgasm. Treatments for physical causes of impotence include medications, hormone therapy, vacuum pumps, surgery and Kegel exercises. Psychological causes of erectile dysfunction may be treated through exercise, counselling, talk therapy and Cognitive Behavioural Therapy (CBT). Low intensity shockwave therapy A new innovation in impotence treatment is electric shock therapy. The therapy is developed by Israeli scientists from Haifa Rambam Medical Centre and is now available at Spire Murrayfield Hospital in Edinburgh, Scotland. Considered safe, non-invasive and pain-free, the electric shock therapy works by stimulating blood flow to the … Continue reading →

Pivotal studies support tadalafil for the treatment of benign prostatic hyperplasia and the treatment of both benign prostatic hyperplasia and erectile dysfunction in patients with both conditions. INDIANAPOLIS, Sept. 21, 2012 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of Cialis(R) (tadalafil) tablets 5 mg for once a day use for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). The CHMP's opinion is now referred to the European Commission, which has the authority to approve medicines for the European Union (EU). The Commission usually issues a decision within one to two months following the CHMP opinion. Tadalafil was approved for the treatment of erectile dysfunction in the EU in 2002. Tadalafil for once a day use was approved for the treatment of erectile dysfunction in the EU in 2007. "If approved by the Commission, tadalafil will be the first and only medication approved in the EU to treat men with both erectile dysfunction and benign prostatic hyperplasia," said Kraig Kinchen, M.D., senior medical director at Lilly. "Since many men who have ED … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/j8q69m/global_erectile_dy) has announced the addition of the "Global Erectile Dysfunction Drug Pipeline Capsule - 2012" report to their offering. Fore Pharma's latest report Global Erectile Dysfunction Drug Pipeline Capsule - 2012' is an outline of all the key research and development (R&D) activities of the global erectile dysfunction drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships. This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals. The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages … Continue reading →

Home national Thai version of 'Viagra' to be launched next month Poungchompoo Prasert The Nation September 6, 2012 1:00 am Viagra sells for about Bt200 per tablet but Sidagra will cost only Bt25 per 50-milligram tablet and Bt45 per 100mg dose, Dr Witit Artavatkul, managing director of the GPO, said yesterday. Sales of the inexpensive product would help stem the outbreak of fake medicine, give hope to people with no access to expensive remedies and address the growing needs of the ageing society, he said. This drug would be popular, he said. The GPO has also improved and expanded its facilities to meet the PICS standard and raise capacity to five billion tablets in preparation for the Asean Economic Community. The state enterprise under the Public Health Ministry was eyeing the market for diabetes, high-blood pressure and HIV/Aids medications in Myanmar, Laos, Cambodia, Vietnam and Malaysia. Pornthep Siriwanarangsan, director-general of the Disease Control Department, also warned the public about dengue fever during this rainy season, as 38,500 cases and 42 deaths have already been reported from January 1-September 4. Last week alone, five people died from this disease, he said. Link: Thai version of 'Viagra' to be launched next month … Continue reading →

Report on Princeton III Meeting on Cardiometabolic Risks and Sexual Health Newswise (CHICAGO)-- Assessment of sexual function should be incorporated into cardiovascular risk evaluation for all men, regardless of the presence or absence of known cardiovascular disease, according to Dr. Ajay Nehra, lead author of a report by the Princeton Consensus (Expert Panel) Conference, a collaboration of 22 international, multispecialty researchers. Nehra is vice chairperson, professor and director of Mens Health in the Department of Urology at Rush University Medical Center in Chicago. Erectile dysfunction (ED) is a red flag in younger men, less than 55 years of age for future cardiac morbidity or mortality death or disease for cardiovascular disease (CVD). In some patients, the time window between onset of ED and a cardiovascular event may be two to five years. Any man with ED should be considered at a substantially higher increase cardiovascular risk until further testing can be done, said Nehra. Erectile dysfunction often occurs in the presence of silent, non-symptomatic cardiovascular disease; and hence this is an opportunity for cardiovascular risk reduction. The panel recommends that younger men, more than 30 years old who experience ED receive a thorough, non invasive cardiovascular disease evaluation. As the … Continue reading →

Published: 2:55PM Thursday August 30, 2012 Source: Newstalk ZB/ONE News The Phoneutria, commonly known as the Brazilian Wandering Spider, is the world's most venomous spider. - Source: Supplied. Venom from the world's deadliest spider could cure erectile dysfunction within 20 minutes. Scientists have discovered the Brazilian Wandering Spider's venom boosts performance by increasing the release of nitric oxide, a chemical that dilates blood vessels and improves blood flow. Brazilian scientists first became interested in the deadly spider's ability to boost sexual performance when victims of bites reported major improvements in their sex lives. Researchers from Brazil and the United States extracted the toxin, called PnTx2-6, from the deadly venom and injected it into rats which had age-related erectile dysfunction, Britain's Daily Mail reports. The researchers found the toxin boosted erections by triggering the release of nitric oxide, which boosts circulation in the male genitals by helping blood vessel walls relax. In a report on their findings, published in The Journal of Sexual Medicine, the researchers said: "The decrease in erectile function associated with age was partially restored 15 to 20 minutes after injection with PnTx2-6." Drugs such as Viagra and Cialis have revolutionised treatment in the last 10 years but … Continue reading →

A study published in The Journal of Sexual Medicine highlights how a deadly spider venom could purportedly treat erectile dysfunction, Medical Daily reported. The Brazilian Wandering Spider, whose deadly bite can kill people within an hour, has venom properties that are of interest to sufferers of ED, according to the studys researchers. Some people who have experienced the spiders bite and lived to talk about it, described a boost in erectile function. Researchers extracted the toxin, which is called PnTx2-6 and injected it into elderly rats. "Nitric oxide synthase (NOS) activity in aged and young cavernosal tissue was increased by incubation with PnTx2-6," wrote Kenia P. Nunes and her colleagues. PnTx2-6 improved genital relaxation therefore improving blood flow in the elderly rats because of increased NOS activity and NO release. Researchers said the effect could be seen in as little as 15 to 20 minutes. Click here for more from Medical Daily. Click here for more from The Journal of Sexual Medicine. Read the original here: Deadly spider venom could treat ED, study says … Continue reading →